Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The medical device firm hopes to accelerate its US launch thanks to early approval
Thursday 31 Aug 2017 Author: Lisa-Marie Janes

Creo Medical (CREO:AIM) is aiming to bring forward its US commercial launch plans after its medical device Speedboat RS2 was approved by the US Food and Drug Administration in only 49 days.

The approval for the disposable device for the treatment of colorectal cancer is six months ahead of schedule and could bode well for future product launches.

‹ Previous2017-08-31Next ›